Altoidas digital biomarkers harness advances in technology to detect brain changes early in the disease process, helping to accelerate early diagnosis for better clinical outcomes and delay of disease onset.

Using an iPad or a Tablet accelerometer, gyroscope and touch screen sensors, Altoida is able to detect micro-errors as both a prognostic and diagnostic digital biomarker. Their technology analyzes visuospatial and executive function during complex activities of daily living through a battery of three tests that ask patients to hide and seek virtual objects in a physical space. With it, medical professionals are able to detect Alzheimers in patients 62+ years old between six and ten years prior to the onset of symptoms and before irreversible damage occurs. They have validated their platform and methodology in more than 12 peer-reviewed journal publications and in more than 200 independent studies.

2100 W Loop S
Houston, TX 77027
United States